MUTUAL NON-DISCLOSURE AGREEMENTMutual Non-Disclosure Agreement • December 27th, 2023 • Astrazeneca PLC • Pharmaceutical preparations
This Mutual Non-Disclosure Agreement (this “Agreement”) is entered into between Icosavax, Inc., a Delaware corporation (“Company”), and the other party named on the signature page hereto (“Other Party”) as of 21-July-2022 (the “Effective Date”), to protect the confidentiality of certain confidential information of Company or of Other Party to be disclosed under this Agreement solely for use in evaluating or pursuing a business relationship between the parties (the “Permitted Use”). Company and Other Party may be referred to herein individually as a “Party” and collectively as the “Parties.”
Second AMENDMENT to MUTUAL NON-DISCLOSURE AGREEMENTNon-Disclosure Agreement • December 27th, 2023 • Astrazeneca PLC • Pharmaceutical preparations
This Second Amendment to Mutual Non-Disclosure Agreement (this “Amendment”) is entered into as of November 26, 2023, by and between Icosavax, Inc., a Delaware corporation (“Icosavax”), and AstraZeneca UK Limited, a company incorporated in England under No. 3674842 whose registered office is at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, England on its behalf and on behalf of its Affiliates (as defined in the Agreement) (“Company”).
FIRST AMENDMENT to MUTUAL NON-DISCLOSURE AGREEMENTNon-Disclosure Agreement • December 27th, 2023 • Astrazeneca PLC • Pharmaceutical preparations
This First Amendment to Mutual Non-Disclosure Agreement (this “Amendment”) is entered into as of November 14, 2023, by and between Icosavax, Inc., a Delaware corporation (“Icosavax”), and AstraZeneca UK Limited, a company incorporated in England under No. 3674842 whose registered office is at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, England on its behalf and on behalf of its Affiliates (as defined in the Agreement) (“Company”).
MUTUAL NON-DISCLOSURE AGREEMENTMutual Non-Disclosure Agreement • December 27th, 2023 • Astrazeneca PLC • Pharmaceutical preparations
This Mutual Non-Disclosure Agreement (this “Agreement”) is entered into as of August 22, 2023 (the “Effective Date”), between Icosavax, Inc., a Delaware corporation (“Icosavax”), and ASTRAZENECA UK LIMITED, a company incorporated in England under No. 3674842 whose registered office is at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, England on its behalf and on behalf of its Affiliates as defined herein (“Company”), on behalf of itself and its Affiliates, to protect the confidentiality of certain confidential information of Icosavax and Company to be disclosed under this Agreement solely for use in evaluating or pursuing a business relationship between the parties related to Icosavax’s VLP technology platform and it’s RSV/hMPV and RSV programs known as IVX-A12 and IVX-121, respectively (the “Permitted Use”). Icosavax and Company may be referred to herein individually as a “Party” and collectively as the “Parties.”
